Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.

Abstract

Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage chemotherapy was 36%; no difference was observed between dexamethasone, cytarabine, cisplatin (10/30, 33%), and gemcitabine, cisplatin, dexamethasone (11/29, 38%) therapy. At one year, event-free survival (EFS) was 16% and overall survival (OS) was 28%. For PTCL patients, who received autologous stem cell transplant, two-year EFS and OS were 21% and 42%, respectively. Patients with PTCL had inferior OS (HR 0.49, p < .0001) and EFS (HR 0.53, p < .0001) compared to B-cell lymphoma. Outcomes for patients with R/R PTCL are poor with currently available therapies.

DOI: 10.1080/10428194.2017.1312379

Cite this paper

@article{Skamene2017SalvageCA, title={Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.}, author={Tanya Skamene and Michael R Crump and Kerry J. Savage and Tony J Reiman and John Kuruvilla and David J Good and David Lebrun and Ralph M. Meyer and Laurie H. Sehn and Denis Souli{\'e}res and Julie Stakiw and Nicole Beatrice Laferriere and Stefano Luminari and Lois E. Shepherd and Marina S Djurfeldt and Liting Zhu and Bingshu E. Chen and Annette Elizabeth Hay}, journal={Leukemia & lymphoma}, year={2017}, volume={58 10}, pages={2319-2327} }